MedReleaf (LEAF) Price Target Increased to C$30.00 by Analysts at Canaccord Genuity
MedReleaf (TSE:LEAF) had its target price lifted by equities researchers at Canaccord Genuity from C$21.50 to C$30.00 in a research note issued to investors on Wednesday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target would indicate a potential upside of 42.38% from the stock’s current price.
Several other equities research analysts also recently commented on LEAF. Eight Capital boosted their target price on MedReleaf from C$13.00 to C$20.00 and gave the stock a “buy” rating in a report on Wednesday, November 15th. Cowen boosted their target price on MedReleaf from C$20.00 to C$36.00 in a report on Monday, January 8th.
MedReleaf (LEAF) traded up C$1.32 during trading on Wednesday, reaching C$21.07. The company’s stock had a trading volume of 494,494 shares, compared to its average volume of 1,011,142. MedReleaf has a twelve month low of C$6.81 and a twelve month high of C$31.25. The company has a market capitalization of $1,970.00 and a P/E ratio of 1,053.50.
TRADEMARK VIOLATION WARNING: This story was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this story on another domain, it was illegally copied and republished in violation of United States and international copyright & trademark law. The legal version of this story can be accessed at https://www.dailypolitical.com/2018/02/14/medreleaf-leaf-price-target-increased-to-c30-00-by-analysts-at-canaccord-genuity.html.
MedReleaf Company Profile
MedReleaf Corp. produces and sells cannabis-based pharmaceutical products in Canada. It offers dried cannabis, cannabis oils, and cannabis oil capsules; and various accessories, including grinders, vaporizers, and lockable containers. The company was incorporated in 2013 and is headquartered in Markham, Canada.
Receive News & Ratings for MedReleaf Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedReleaf and related companies with MarketBeat.com's FREE daily email newsletter.